Transaction DateRecipientSharesTypePriceValue
14th January 2021William Hewitt Robinson2,259Open or private sale$15.06$34,010.83
13th January 2021William Hewitt Robinson2,741Open or private sale$15.05$41,238.62
4th January 2021Bros. Advisors Lp Baker10,060Open or private sale$220.50$2,218,230.00
4th January 2021Bros. Advisors Lp Baker111,094Open or private sale$220.50$24,496,227.00
31st December 2020Bros. Advisors Lp Baker343Grant/award etc.$0.00
31st December 2020Bros. Advisors Lp Baker343Grant/award etc.$0.00
17th December 2020Norman Michael Greenberg5,000Exercise of derivative$4.56$22,800.00
17th December 2020Norman Michael Greenberg5,000Open or private sale$16.61$83,051.00
11th December 2020Tito Serafini10,000Open or private sale$15.87$158,735.00
4th December 2020Bros. Advisors Lp Baker125,513Open or private sale$220.50$27,675,616.50
Atreca logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.

Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients.

Ticker: BCEL
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1532346
Employees: 113
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags